AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Potassium voltage-gated channel subfamily C member 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries for ion channels.

 Fig. 1. The sreening workflow of Receptor.AI

It includes extensive molecular simulations of the channel in its native membrane environment in open, closed and inactivated forms and the ensemble virtual screening accounting for conformational mobility in each of these states. Tentative binding pockets are considered inside the pore, in the gating region and in the allosteric locations to cover the whole spectrum of possible mechanisms of action.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q96PR1

UPID:

KCNC2_HUMAN

Alternative names:

Shaw-like potassium channel; Voltage-gated potassium channel Kv3.2

Alternative UPACC:

Q96PR1; B7Z231; F5H030; J3KPP5; Q4LE77; Q86W09; Q8N1V9; Q96PR0

Background:

The Potassium voltage-gated channel subfamily C member 2, also known as Kv3.2, is a critical component in the regulation of transmembrane potassium transport in excitable membranes, predominantly in the brain. It plays a pivotal role in the fast action potential repolarization and high-frequency firing in central nervous system neurons. Kv3.2 can form both homotetrameric and heterotetrameric channels, influencing its electrical properties and interaction with other proteins.

Therapeutic significance:

Developmental and epileptic encephalopathy 103 (DEE103) is a severe condition linked to mutations affecting Kv3.2. This disease highlights the protein's crucial role in neurological health and underscores the potential of targeting Kv3.2 in therapeutic strategies aimed at ameliorating symptoms or altering the disease course in DEE103 and possibly other neurological disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.